Reclast, the first once-a-YEAR bisphosphonate infusion for postmenopausal osteoporosis
View FDA's preliminary statement concerning bisphosphonates and atrial fibrillation
Women will be asking about Reclast, the first once-a-YEAR bisphosphonate infusion for postmenopausal osteoporosis.
Reclast (zoledronic acid) is already approved for Paget's disease. Zoledronic acid is also what's in Zometa for cancer patients.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote